What do the evolutionary studies of tumor progression--and heterogeneity--teach us about timing, longitudinal sampling, serial biopsies, and sampling sites for NGS-based genomic testing in metastatic cancer?

What do the evolutionary studies of tumor progression--and heterogeneity--teach us about timing, longitudinal sampling, serial biopsies, and sampling sites for NGS-based genomic testing in metastatic cancer?

What do the evolutionary studies of tumor progression—and heterogeneity—teach us about timing, longitudinal sampling, serial biopsies, and sampling sites for NGS-based genomic testing in patients with metastatic cancer?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Samuel Klempner, MD

Samuel Klempner, MD

Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA